Licensing & Strategic Alliances: How to Avoid Leaving Value on the Table
- Discussing examples of deal evaluation and success, including details of the process
- Sharing how early-stage programs can successfully navigate the “show me data” barrier with pharma, and overcome the activation barrier to licencing technologies between equal sized biotech
- Debating recent regulatory and emerging technology shifts, and how these will shape licensing deals for targeted therapies worldwide